Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01093 CSPC PHARMA
RTNominal up6.600 +0.080 (+1.227%)
Others

18/10/2019 17:19

CSPC Pharma (01093) antibody gets disease designation

[ET Net News Agency, 18 October 2019] CSPC Pharmaceutical Group Limited (01093) said
that humanized connexin 43 (Cx43) monoclonal antibody (ALMB-0168), a product candidate
independently developed by its subsidiary AlaMab Therapeutics Inc., was granted rare
paediatric disease designation by the U.S. Food and Drug Administration (FDA) for the
treatment of osteosarcoma. It represents another designation of ALMB-0168 in addition to
the orphan-drug designation granted by the U.S. FDA in September 2019.
ALMB-0168 is a first-in-class humanized monoclonal antibody agonist for hemichannel Cx43
membrane protein. Through the activation of Cx43 protein to release tumour-inhibiting
cytokines, ALMB-0168 has shown to effectively inhibit osteosarcoma and bone metastasis in
pre-clinical in vitro and in vivo animal studies. (RC)

Back to Others

Remark: Real time quote last updated: 26/04/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.